The efficacy and tolerability of rifampicin in Burmese patients with lepromatous leprosy
v. 3 n. 1 (1978), Artigos originais
v. 3 n. 1 (1978)

The efficacy and tolerability of rifampicin in Burmese patients with lepromatous leprosy

Artigos originais
https://doi.org/10.47878/hi.1978.v3.35639
Publicado 30-06-1978
TIN SHWE
M. B., B. S., D.P.T.M. (Regn.), D.C.T.M., Ph.D. (Lond.) Leprosy Hospital Htaukkyant, Rangoon, Burma.
KYAW LWIN
M. B., B. S., D.P.H. Department of Health, Ministry of Health, Rangoon, Burma.
KYO THWE
M. B., B. S.: F.R.C.P.E., D.T.M.. H. (Loud.). Department of Medicine, Institute of Medicine, Rangoon, Burma.
PDF (English)

Palavras-chave

Virchowian hanseniasis
Therapy
Rifampicin

Como Citar

1.
SHWE T, LWIN K, THWE K. The efficacy and tolerability of rifampicin in Burmese patients with lepromatous leprosy. Hansen. Int. [Internet]. 30º de junho de 1978 [citado 13º de novembro de 2024];3(1):30-41. Disponível em: https://periodicos.saude.sp.gov.br/hansenologia/article/view/35639
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Baixar Citação

Endnote/Zotero/Mendeley (RIS) BibTeX

Resumo

Seventy-one Burmese adult patients with lepromatous leprosy were treated with various regimens of rifampicin monotherapy, 450 mg. daily for 60 days or 900 mg. once weekly for 12 weeks or 450 mg. daily for six months. Of the patients, 18 had relapsed after stopping DDS therapy, 20 were intolerant of DDS, 18 were DDS resistant and 15 had received no previous treatment. Rifampicin produced a 75% reduction in the size of skin nodules in two thirds of the patients and a complete disappearance of nodules in the others. After one month drug treatment the MI fell to zero but the BI remained unchanged. The once weekly regimen was as effective as the daily treatment. Four patients had to be withdrawn due to ENL reactions.

https://doi.org/10.47878/hi.1978.v3.35639
PDF (English)

Referências

1. LEVY, L.; SHEPARD, C. C.; FASAL, P. The bactericidal effect of rifampicin on M. leprae in man: (a) single doses of 600, 900 and 1200 mg; and (b) daily doses of 300 mg. In: JOINT LEPROSY RESEARCH CONFERENCE, 10th, Bethesda, 1975 apud Int. J. Lepr., 44(1/2): 183-187, 1976.
2. LEVY, L.; SHEPARD, C. C.; FASAL, P. Death of M. leprae following treatment of leprosy patients with 1500 mg rifampin in a single dose. In: INTERNATIONAL LEPROSY CONGRESS, 10th, Bergen, 1973 apud Int. J. Lepr., 41(4):490, 1973.
3. PATIYN, S. R.; DOCKX, P.; ROLLIER, M. T.; ROLLIER, R.; SAERENS, E. J. Mycobacterium leprae persisters after treatment with dapsone and rifampicin. In: JOINT LEPROSY RESEARCH CONFERENCE, 10th, Bethesda, 1975 apud Int. J. Lepr., 44(1/2):154-158,.1976.
4. PATTYN, S. R.; ROLLIER, M. T.; ROLLIER, R.; SAERENS, E. J.; DOCKX, P. A controlled clinical trial of continuous and intermittent rifampicin therapy during an initial three months period in lepromatous leprosy: final analysis. Lepr. Rev., 46(2 suppl.):129-139, 1975.
5. REES, R. J. W.; PEARSON, J. M. H.; WATERS, M. F. R. Experimental and clinical studies of rifampicin in treatment of leprosy. Br. Med. J., 1:89-92, 1970.
6. REFS, R. J. W.; WATERS, M. F. R.; PEARSON, J. M. H.; HELMY, H. S.; LAING, A. B. G. Long-term treatment of dapsone-resistant leprosy with rifampicin: clinical and bacteriological studies. In: JOINT LEPROSY RESEARCH CONFERENCE, 10th, Bethesda, 1975 apud Int. J. Lepr., 44(1/2):159-169, 1976.
7. SHEPARD, C. C.; LEVY, L.; FASAL, P. Rapid bactericidal effect of rifampin on Mycobacterium leprae. Am. J. Trop. Med. Hyg., 2I:446-449, 1972.

Este periódico está licenciado sob uma Creative Commons Attribution 4.0 International License.

Downloads

Não há dados estatísticos.